SEARCH

SEARCH BY CITATION

References

  • 1
    Novellino L, Castelli C, Parmiani G. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immuno Immunother 2005; 54: 187207.
  • 2
    Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10: 2817.
  • 3
    Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 90915.
  • 4
    Sato Y, Shomura H, Maeda Y et al . Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 2003; 94: 8028.
  • 5
    Mine T, Gouhara R, Hida N et al . Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci 2003; 94: 54856.
  • 6
    Tsuda N, Mochizuki K, Harada M et al . Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 2004; 27: 6072.
  • 7
    Mine T, Sato Y, Noguchi M et al . Humoral responses to peptides correlated with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 2004; 10: 92937.
  • 8
    Yamada A, Itoh K. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 2006; 97: 9706.
  • 9
    Noguchi M, Itoh K, Yao A et al . Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients. Prostate 2005; 63: 112.
  • 10
    Shirasaka T, Nakano K, Takechi T et al . Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypridine–1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996; 56: 26026.
  • 11
    Shirasaka T, Shimamoto Y, Ohshimo H et al . Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1995; 7: 54857.
  • 12
    Osigi H, Takada N, Takemura M et al . Oral fluoropyrimidine anticancer drugs TS-1 for gastric cancer patients with peritoneal dissemination. Oncol Rep 2002; 9: 81115.
  • 13
    Hida N, Maeda Y, Katagiri K et al . A new culture protocol to detect peptide-specific cytotixic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 2002; 51: 21928.
  • 14
    Komatsu N, Shichijo S, Nakagawa M, Itoh K. New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 2004; 64: 111.
  • 15
    Wang Y, Harada M, Yano H et al . Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adencarcinoma. J Immnother 2005; 8: 5341.
  • 16
    Matsueda S, Yao A, Ishihara Y et al . A prostate stem cell antigen-derived peptide immunogenic in HLA-A24+ prostate cancer patients. Prostate 2004; 60: 20513.
  • 17
    Gomi S, Nakao M, Niiya F et al . A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted tumor-specific CTLs. J Mmunol 1999; 163: 49945004.
  • 18
    Ogata R, Matsueda S, Yao A, Noguchi M, Itoh K, Harada M. Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients. Prostate 2004; 60: 27381.
  • 19
    Yamada A, Kawano K, Koga M, Matsmoto T, Itoh K. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 2001; 61: 645966.
  • 20
    Yang D, Nakao M, Shichijo S et al . Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999; 59: 405663.
  • 21
    Harashima N, Tanaka K, Sasatomi T et al . Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases. Eur J Immunol 2001; 31: 32332.
  • 22
    Ito M, Shichijo S, Tsuda N et al . Molecular basis of T cell-mediated recognition of pancreatic cancer cells. Cancer Res 2001; 61: 203846.
  • 23
    Imai N, Harashima N, Ito M et al . Identification of Lck-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with distant metastases. Int J Cancer 2001; 94: 23742.
  • 24
    Ito M, Shichijo S, Miyagi Y et al . Identification of SART3-derived peptides capable of inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. Int J Cancer 2000; 88: 6339.
  • 25
    Ishihara Y, Harada M, Azuma K et al . HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients. Int J Oncol 2004; 24: 96775.
  • 26
    Harada M, Matsueda S, Yao A, Ogata R, Noguchi M, Itoh K. Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients. Oncol Rep 2004; 12: 6017.
  • 27
    Shomura H, Shichijo S, Matsueda S et al . Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2+ cancer patients. Br J Cancer 2004; 90: 156371.
  • 28
    Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004; 22: 53162.
  • 29
    Chattopadhyay S, Chakraborty NG, Mukherji B. Regulatory T cells and tumor immunity. Cancer Immunol Immunother 2005; 54: 115361.
  • 30
    Kitano H. Cancer robustness: tumor tactics. Nature 2003; 426: 125.
  • 31
    Kitano H. Cancer as a robust system: implications for anticancer therapy. Nat Rev 2004; 4: 22735.
  • 32
    Li Q, Pan PY, Gu P, Xu D, Cehn SH. Role of immature myeloid Gr-1+ cells in the development of antitumor immunity. Cancer Res 2004; 64: 11309.
  • 33
    Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005; 175: 458392.